01187 可孚醫療
COFOE MEDICAL
COFOE MEDICAL
| Register Close | 2026/04/30 IPO Closing in 2 Days |
| Listing Date | 2026/05/06 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Cofoe Medical Technology Co. is a provider of home care medical devices in China. According to the report, in terms of the 2024 domestic revenue, the Group ranked second among all home care medical devices providers in China, with a market share of 2.1%.
--
The Group strategically focuses on five main categories of home care medical devices that it believes enjoy strong growth potential and significant market demands in line. These include rehabilitation aids products, medical care products, health monitoring products, respiratory support products and TCM therapy and other products.
--
As of March 9, 2026, the Group’s product portfolio encompassed over 200 product categories with over ten thousand SKUs, it primarily had 11 proprietary brands and sold products mainly under 16 third-party brands. The Group generated revenue primarily from the sales of medical and wellness products, OEM/ODM business and others.
--
As of December 31, 2025, the Group held 699 patents, had four major manufacturing bases in China and 668 self-owned stores, among which, 618 of them were its “JOYOR HearingCare” centers, covering 128 cities across China. The Group’s customers primarily include e-commerce platforms, pharmacy chains, distributors and individual consumers.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 27.00M H shares |
| No. of International Offer Shares | 24.30M H shares |
| No. of HK Offer Shares | 2.70M H shares |
| Offer Price | $39.33 |
| Stock Code | 1187 |
| Sponsor(s) | Huatai Financial Holdings (Hong Kong) Limited, BNP Paribas Securities (Asia) Limited |
| Underwriter(s) | Huatai Financial Holdings (Hong Kong) Limited, BNP Paribas Securities (Asia) Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Apr 27 (Mon) - noon, Apr 30 (Thu) |
| Price Determination Date | May 04 (Mon) |
| Result Announcement Date | On or before May 05 (Tue) |
| Result Announcement Date | On or before May 05 (Tue) |
| Result Announcement Date | On or before May 06 (Wed) |
| Dealings in Shares commence on | May 06, 2026. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $39.33 |
| Capitalization | 14.08B |
| NAV / share ($) | $26.32 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 39.33, the net proceeds raised would be HKD 1.01B, of which |
| 30% : Used for global expansion |
| 30% : Ongoing product research and development and technological innovation, including our AI and Internet of Things applications |
| 20% : Expanding domestic sales channels and distribution network |
| 10% : Branding and marketing activities |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).